Table 1.
Clinical trials using human fetal tissue and HESCs
| Disease | Source | Phase | Clinical trial.gov identifier | Cell type transplanted | Center (PI) |
|---|---|---|---|---|---|
| Retinitis Pigmentosa | Human fetal tissue | I/II | NCT02464436 | Retinal progenitor cell | ReNeuron, Guildford, UK |
| Retinitis Pigmentosa | Human fetal tissue | I/II | NCT02320812 | Human retinal progenitor cell | jCyte, Inc, CA USA |
| Retinitis Pigmentosa | Human fetal tissue | Phase II | NCT03073733 | Human retinal progenitor cell | jCyte, Inc, CA USA |
| AMD | Human fetal tissue | Phase II | NCT00346060 | Human fetal retinal sheet | Kentucky, USA |
| Retinitis Pigmentosa | Human fetal tissue | Phase II | NCT00345917 | Human fetal retinal sheet | Kentucky, USA |
| Stargardt’s Macular Dystrophy | HESC | Phase I/II | NCT01345006 | RPE | Astellas, USA |
| Dry AMD | HESC | Phase I/II | NCT01344993 | RPE | Astellas, USA |
| AMD | HESC | Phase I/II | NCT02286089 | RPE | Cell Cure, Israel |
| Dry AMD | HESC | Phase I/II | NCT02590692 | CPCB-RPE1 | Regenerative Patch Technologies, LLC, CA, USA |